Status and phase
Conditions
Treatments
About
To explore the dose and safety of thalidomide for the prevention and treatment of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP)
Full description
To increase the evidence of thalidomide for the prevention of RCCEP, the investigators will explore the dose of thalidomide for the prevention of RCCEP in participants with esophageal squamous cell carcinoma and non-small cell lung cancer who were scheduled to receive camrelizumab combined with platinum-based chemotherapy; To increase the evidence of thalidomide for the treatment of RCCEP, the investigators will explore the dose of thalidomide for the treatment of ≥G2 RCCEP in participants with esophageal squamous cell carcinoma and non-small cell lung cancer with camrelizumab
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Prevention cohort 1:
Treatment cohort 2:
Exclusion criteria
Prevention cohort 1:
Treatment cohort 2:
Primary purpose
Allocation
Interventional model
Masking
132 participants in 4 patient groups
Loading...
Central trial contact
Ying Liu, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal